- Home
- YYAI vs PHGE Comparison
YYAI vs PHGE Comparison
Compare YYAI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYAI
- PHGE
- Stock Information
- Founded
- YYAI 2015
- PHGE 2015
- Country
- YYAI Hong Kong
- PHGE Israel
- Employees
- YYAI N/A
- PHGE N/A
- Industry
- YYAI
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- YYAI
- PHGE Health Care
- Exchange
- YYAI NYSE
- PHGE Nasdaq
- Market Cap
- YYAI 12.1M
- PHGE 13.3M
- IPO Year
- YYAI N/A
- PHGE N/A
- Fundamental
- Price
- YYAI $0.64
- PHGE $0.96
- Analyst Decision
- YYAI
- PHGE Strong Buy
- Analyst Count
- YYAI 0
- PHGE 2
- Target Price
- YYAI N/A
- PHGE $13.50
- AVG Volume (30 Days)
- YYAI 1.7M
- PHGE 48.8K
- Earning Date
- YYAI 03-04-2025
- PHGE 04-02-2025
- Dividend Yield
- YYAI N/A
- PHGE N/A
- EPS Growth
- YYAI N/A
- PHGE N/A
- EPS
- YYAI N/A
- PHGE N/A
- Revenue
- YYAI N/A
- PHGE N/A
- Revenue This Year
- YYAI N/A
- PHGE N/A
- Revenue Next Year
- YYAI N/A
- PHGE N/A
- P/E Ratio
- YYAI N/A
- PHGE N/A
- Revenue Growth
- YYAI N/A
- PHGE N/A
- 52 Week Low
- YYAI $0.35
- PHGE $0.48
- 52 Week High
- YYAI $53.00
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- YYAI 47.76
- PHGE 65.22
- Support Level
- YYAI $0.35
- PHGE $0.87
- Resistance Level
- YYAI $0.67
- PHGE $0.99
- Average True Range (ATR)
- YYAI 0.07
- PHGE 0.08
- MACD
- YYAI 0.07
- PHGE 0.01
- Stochastic Oscillator
- YYAI 90.66
- PHGE 89.20
About YYAI CONNEXA SPORTS TECHNOLOGIES IN
Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.